Back
Verrica Pharmaceuticals, Inc. 10K Form
Buy
59
VRCA
Verrica Pharmaceuticals, Inc.
Last Price:
$7.87
Seasonality Move:
19.5%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-08-05 | 10Q | VRCA/Verrica Pharmaceuticals, Inc. Quarterly |
| 2020-05-07 | 10Q | VRCA/Verrica Pharmaceuticals, Inc. Quarterly |
| 2020-03-13 | 10K | VRCA/Verrica Pharmaceuticals, Inc. Annual |
| 2019-11-06 | 10Q | VRCA/Verrica Pharmaceuticals, Inc. Quarterly |
| 2019-08-07 | 10Q | VRCA/Verrica Pharmaceuticals, Inc. Quarterly |
| 2019-05-07 | 10Q | VRCA/Verrica Pharmaceuticals, Inc. Quarterly |
Receive VRCA News And Ratings
See the #1 stock for the next 7 days that we like better than VRCA
VRCA Financial Statistics
Sales & Book Value
| Annual Sales: | $7.6M |
|---|---|
| Cash Flow: | $9.7M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-1.80 |
| Price / Book: | 192.69 |
Profitability
| EPS (TTM): | -2.51660 |
|---|---|
| Net Income (TTM): | $-26M |
| Gross Margin: | $4.8M |
| Return on Equity: | -2619.46% |
| Return on Assets: | -62.02% |
Verrica Pharmaceuticals, Inc. Earnings Forecast
Key Verrica Pharmaceuticals, Inc. Financial Ratios
-
The Gross Profit Margin over the past 9 years for VRCA is 63.79%.
-
The Selling, General & Administrative Expenses for VRCA have been equal to 777.45% of Gross Profit Margin.
-
The Research & Development expenses have been 156.49% of Revenue.
-
The Net Earning history of VRCA is -1,012.15% of Total Revenues.
-
Per Share Earnings over the last 9 years have been positive in 3 years.
Verrica Pharmaceuticals, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | VRCA |
| CUSIP: | 92511W |
| Website: | verrica.com |
Debt
| Debt-to-Equity Ratio: | -2.1 |
|---|---|
| Current Ratio: | 1.19 |
| Quick Ratio: | 0.98 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
VRCA Technical Analysis vs Fundamental Analysis
Buy
59
Verrica Pharmaceuticals, Inc. (VRCA)
is a Buy
Is Verrica Pharmaceuticals, Inc. a Buy or a Sell?
-
Verrica Pharmaceuticals, Inc. stock is rated a BuyThe current Verrica Pharmaceuticals, Inc. [VRCA] share price is $7.82. The Score for VRCA is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.